Vericiguat

Effects of Vericiguat on Peripheral Vascular Function and Resting/Exercise Hemodynamics in Patients With Heart Failure With Reduced Ejection Fraction: An Exploratory Pilot Study.

Journal: Journal of cardiovascular pharmacology and therapeutics

Published: June 23, 2026

Efficacy and Safety of Vericiguat in Heart Failure: A Systematic Review and Meta-Analysis.

Journal: Cureus

Published: May 11, 2026

Use of vericiguat in the VICTOR trial: a study that is difficult to interpret.

Journal: European heart journal supplements : journal of the European Society of Cardiology

Published: May 08, 2026

Vericiguat Attenuates Vascular Calcification by Cyclic Guanosine Monophosphate-Protein Kinase G Pathway Mediated Suppression of Matrix Metalloproteinase 10.

Journal: Journal of the American Heart Association

Published: May 06, 2026

Temporal Changes in Guideline-Directed Medical Therapy Score and Clinical Outcomes in Patients with Heart Failure.

Journal: European heart journal. Quality of care & clinical outcomes

Published: May 06, 2026

Vericiguat, a soluble guanylate cyclase stimulator, regulates heart failure-enhanced atrial and pulmonary vein arrhythmogenesis.

Journal: Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie

Published: April 25, 2026

Efficacy and safety of vericiguat in patients with heart failure with reduced ejection fraction and asymptomatic hypotension: insights from a multicenter observational cohort study.

Journal: BMC cardiovascular disorders

Published: April 20, 2026

Correction to: Vericiguat and mortality in heart failure and reduced ejection fraction: the VICTOR trial.

Journal: European heart journal

Published: April 16, 2026

Association Between Different Vericiguat Dose Exposures, Concomitant Quadruple Heart Failure Therapy, and Myocardial Fibrosis Burden in Older Adults with Worsening Heart Failure with Reduced Ejection Fraction.

Journal: Anatolian journal of cardiology

Published: April 07, 2026

Changes in Natriuretic Peptide Levels and Cardiac Structure in Patients Treated With Vericiguat　- VERIFY-HF Registry.

Journal: Circulation journal : official journal of the Japanese Circulation Society

Published: March 29, 2026

Macrophage-driven remodeling in the infarcted myocardium: emerging roles for vericiguat.

Journal: American journal of physiology. Heart and circulatory physiology

Published: March 19, 2026

Efficacy of Vericiguat in Acute Heart Failure: A Target Trial Emulation Study.

Journal: Journal of the American Heart Association

Published: March 18, 2026

Effects of Vericiguat on Peripheral Vascular Function and Resting/Exercise Hemodynamics in Patients With Heart Failure With Reduced Ejection Fraction: An Exploratory Pilot Study.

Effects of Vericiguat on Peripheral Vascular Function and Resting/Exercise Hemodynamics in Patients With Heart Failure With Reduced Ejection Fraction: An Exploratory Pilot Study.

Efficacy and Safety of Vericiguat in Heart Failure: A Systematic Review and Meta-Analysis.

Efficacy and Safety of Vericiguat in Heart Failure: A Systematic Review and Meta-Analysis.

Use of vericiguat in the VICTOR trial: a study that is difficult to interpret.

Use of vericiguat in the VICTOR trial: a study that is difficult to interpret.

Vericiguat Attenuates Vascular Calcification by Cyclic Guanosine Monophosphate-Protein Kinase G Pathway Mediated Suppression of Matrix Metalloproteinase 10.

Vericiguat Attenuates Vascular Calcification by Cyclic Guanosine Monophosphate-Protein Kinase G Pathway Mediated Suppression of Matrix Metalloproteinase 10.

Temporal Changes in Guideline-Directed Medical Therapy Score and Clinical Outcomes in Patients with Heart Failure.

Temporal Changes in Guideline-Directed Medical Therapy Score and Clinical Outcomes in Patients with Heart Failure.

Vericiguat, a soluble guanylate cyclase stimulator, regulates heart failure-enhanced atrial and pulmonary vein arrhythmogenesis.

Vericiguat, a soluble guanylate cyclase stimulator, regulates heart failure-enhanced atrial and pulmonary vein arrhythmogenesis.

Efficacy and safety of vericiguat in patients with heart failure with reduced ejection fraction and asymptomatic hypotension: insights from a multicenter observational cohort study.

Efficacy and safety of vericiguat in patients with heart failure with reduced ejection fraction and asymptomatic hypotension: insights from a multicenter observational cohort study.

Correction to: Vericiguat and mortality in heart failure and reduced ejection fraction: the VICTOR trial.

Correction to: Vericiguat and mortality in heart failure and reduced ejection fraction: the VICTOR trial.

Association Between Different Vericiguat Dose Exposures, Concomitant Quadruple Heart Failure Therapy, and Myocardial Fibrosis Burden in Older Adults with Worsening Heart Failure with Reduced Ejection Fraction.

Association Between Different Vericiguat Dose Exposures, Concomitant Quadruple Heart Failure Therapy, and Myocardial Fibrosis Burden in Older Adults with Worsening Heart Failure with Reduced Ejection Fraction.

Changes in Natriuretic Peptide Levels and Cardiac Structure in Patients Treated With Vericiguat - VERIFY-HF Registry.

Changes in Natriuretic Peptide Levels and Cardiac Structure in Patients Treated With Vericiguat - VERIFY-HF Registry.

Macrophage-driven remodeling in the infarcted myocardium: emerging roles for vericiguat.

Macrophage-driven remodeling in the infarcted myocardium: emerging roles for vericiguat.

Efficacy of Vericiguat in Acute Heart Failure: A Target Trial Emulation Study.

Efficacy of Vericiguat in Acute Heart Failure: A Target Trial Emulation Study.

Changes in Natriuretic Peptide Levels and Cardiac Structure in Patients Treated With Vericiguat　- VERIFY-HF Registry.

Changes in Natriuretic Peptide Levels and Cardiac Structure in Patients Treated With Vericiguat　- VERIFY-HF Registry.